文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

肥厚型心肌病线粒体功能障碍与心肌细胞结构破坏相关

Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration.
PubMed 文献 · Eur Heart J · 2023-01-01

研究对59例肥厚型心肌病(HCM)患者室间隔心肌切除组织行呼吸测定,评估氧化磷酸化和脂肪酸氧化。线粒体功能障碍主要表现为NADH相关呼吸受损,且与心肌细胞结构破坏密切相关;在基因型阴性患者中NADH相关呼吸与室间隔增厚相关。提高NADH驱动呼吸的治疗可改善呼吸功能。

要点

  • HCM患者线粒体功能障碍主要表现为NADH相关呼吸受损。
  • 线粒体功能障碍由心肌细胞结构破坏解释,而非线粒体数量减少或碎片化。
  • 基因型阴性HCM中NADH相关呼吸与室间隔增厚相关,线粒体靶向治疗可能尤其获益。

核心结论

  • HCM线粒体功能障碍由心肌细胞结构破坏解释,并与基因型阴性患者的室间隔肥厚相关。
  • 尽管心肌重构严重,线粒体对恢复呼吸功能的治疗有反应,提示线粒体可作为HCM药物靶点。

研究设计与样本

  • 对59例HCM患者室间隔心肌切除组织行呼吸测定,评估氧化磷酸化和脂肪酸氧化。

主要发现

  • 线粒体功能障碍最突出表现为NADH相关呼吸受损。
  • 基因型阴性患者中,室间隔厚度指数≥10者NADH相关呼吸较<10者显著降低,基因型阳性患者无此差异。
  • 线粒体功能障碍不能由线粒体丰度减少或碎片化解释,而与线粒体相对肌原纤维排列紊乱百分比强相关。
  • 预孵育心磷脂稳定药物elamipretide和升高线粒体NAD+水平均增强NADH相关呼吸。

临床怎么用

  • 线粒体靶向治疗可能尤其使基因型阴性HCM患者获益,因该亚组线粒体损伤与室间隔增厚紧密关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Genetic hypertrophic cardiomyopathy (HCM) is caused by mutations in sarcomere protein-encoding genes (i.e. genotype-positive HCM). In an increasing number of patients, HCM occurs in the absence of a mutation (i.e. genotype-negative HCM). Mitochondrial dysfunction is thought to be a key driver of pathological remodelling in HCM. Reports of mitochondrial respiratory function and specific disease-modifying treatment options in patients with HCM are scarce. METHODS AND RESULTS: Respirometry was performed on septal myectomy tissue from patients with HCM (n = 59) to evaluate oxidative phosphorylation and fatty acid oxidation. Mitochondrial dysfunction was most notably reflected by impaired NADH-linked respiration. In genotype-negative patients, but not genotype-positive patients, NADH-linked respiration was markedly depressed in patients with an indexed septal thickness ≥10 compared with <10. Mitochondrial dysfunction was not explained by reduced abundance or fragmentation of mitochondria, as evaluated by transmission electron microscopy. Rather, improper organization of mitochondria relative to myofibrils (expressed as a percentage of disorganized mitochondria) was strongly associated with mitochondrial dysfunction. Pre-incubation with the cardiolipin-stabilizing drug elamipretide and raising mitochondrial NAD+ levels both boosted NADH-linked respiration. CONCLUSION: Mitochondrial dysfunction is explained by cardiomyocyte architecture disruption and is linked to septal hypertrophy in genotype-negative HCM. Despite severe myocardial remodelling mitochondria were responsive to treatments aimed at restoring respiratory function, eliciting the mitochondria as a drug target to prevent and ameliorate cardiac disease in HCM. Mitochondria-targeting therapy may particularly benefit genotype-negative patients with HCM, given the tight link between mitochondrial impairment and septal thickening in this subpopulation.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Nollet EE, Duursma I, Rozenbaum A, et al. Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration. Eur Heart J. 2023. PMID: 36734059. doi:10.1093/eurheartj/ehad028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。